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Sexual selection and cancer biology
Joshua B. Rubin
Darwin suggested that when males and females 
“differ in structure, colour or ornament” it is the result of 
sexual selection (“On the origin of species” by Charles 
Darwin). It has become increasingly apparent that in 
addition to overt sexual dimorphisms, there are substantial 
differences in underlying male and female biology that 
have relevance to human health and disease. It was 
recently reported that male astrocytes exhibit markedly 
greater tumorigenic responses to combined loss of 
neurofibromin and p53 function and activation of the EGF 
receptor pathway than do female astrocytes [1]. Moreover, 
differential RB regulation was shown to be essential for 
the manifestation of sex differences in tumorigenicity. It 
was suggested that cell intrinsic dissimilarities in tumor 
suppressor and oncogene effects provided novel insight 
into the basis for disparities that exist in glioblastoma 
rates and outcomes. It is likely however, that these 
findings are more broadly relevant to the overall greater 
rate of cancer diagnoses and cancer deaths in males. The 
experimental paradigm that was used for measuring sex-
specific effects provides new opportunities and possibly, 
new requirements for basic and translational research. 
What makes this position so compelling is the ways in 
which sex differences in tumorigenicity can be related to 
fundamental sexual dimorphisms in growth, the vigorous 
evolutionary forces that created them, and the multiple 
developmental mechanisms that execute sex-specific 
growth strategies [2].
As any parent knows normative growth for boys and 
girls is substantially different. Not only do males typically 
grow to a greater size than females, but they also grow 
for a longer period of time. Sex related size differences 
that result in larger males are pervasive throughout the 
animal kingdom with few exceptions. Greater male size 
is a manifestation of greater male growth rates from the 
pre-implantation stage of embryogenesis to adulthood, 
with the brief period of exception during early puberty. 
The important questions are: Why are there differences 
in growth between males and females? What are the 
mechanistic foundations of sexual dimorphism? What 
are the implications of sexual dimorphism for the risks 
and manifestations of disorders in growth regulation such 
as cancer? What are the opportunities and requirements 
for studying sex differences in lab-based and clinical 
investigations in oncology?
Darwin recognized that sex differences were 
evolutionarily determined and he promulgated a theory 
of sexual selection, a distinct evolutionary process for 
shaping phenotypic differences within a species through 
competition between individuals of the same sex for 
reproductive success. Markedly different reproductive 
pressures on males and females have produced colorfully 
distinct strategies for success.  Male reproductive success 
is limited by access to mates and consequently their 
reproductive strategy involves body size and displays 
that enhance their attractiveness to females and their 
ability to vanquish other males.  This has been referred 
to as the “live fast, die young” blueprint for success [3]. 
Resources, not mates, limit female reproductive success. 
Consequently large body size and ostentatious displays 
are counterproductive. Instead, balancing growth with 
viability, particularly from gestation through weaning 
stages of offspring development is paramount for female 
reproductive success. Thus, there are differing growth 
optima for males and females and genetic conflict in 
growth regulatory pathways [4]. 
It is appealing to think about the relationship 
between differences in body size, the numbers of cells 
required and cancer risk as a simple equation in which 
bigger size and more cells results in greater cancer risk. 
However, the normal distribution of size between males 
and females overlaps significantly and is not likely to 
be the primary determinant of differences in cancer 
risk.  Instead, the importance of sex-specific growth to 
cancer biology is more likely to lie in the homeostatic 
mechanisms that are in place to defend and preserve the 
differing optima. Normal distribution in size is a balance 
between male-derived influences that favor being larger 
(e.g. paternal imprinting of the H19 locus) and female-
derived influences that favor being smaller (e.g. maternal 
imprinting of the IGF2 locus).  The critical question may 
be, what happens when perturbations in growth regulation 
occur that shift normal growth towards greater or smaller 
growth rates and size. If loss of growth control were to 
move growth closer to the male optima but further from 
the female optima would the counter-regulatory response 
be the same, or would this be “allowed” in the male cell 
but “disallowed” in the female cell?  This may be the 
key to the relationship between differences in growth 
and cancer at the earliest stages of cancer initiation when 
loss of tumor suppressor function or gain of oncogene 
function first alters growth. This could be the basis for the 
differential effects of combined loss of neurofibromin and 
p53 function.
Developmental consequences of in utero stressors 
provide important insight into these issues. Multiple 
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studies of the impact that maternal nutrient deprivation 
and other in utero stressors have on fetal development 
reveal sex differences in viability and body size at birth 
[5]. Normal growth rates but increased fetal demise 
is more commonly observed for males while greater 
viability but decreased body size is more commonly 
observed for females.  Underlying these differences are 
epigenetic mechanisms that preserve metabolism and 
growth stimulatory pathways in males and differing 
epigenetic mechanisms that slow growth, reduce nutrient 
requirements and increase immune activity in females [6]. 
A related set of observations suggests that epigenetic sex 
differences like these may be prevalent. The bed nucleus of 
the stria terminalis (BNST) is a highly sexually dimorphic 
region of the brain. An analysis of histone bivalency in 
male and female BNST revealed H3K4/K27 trimethylation 
at developmental and growth regulatory genes in males 
but in synaptic function genes in females [7]. These data 
may indicate that in response to perturbations in growth, 
males are poised to maintain their size, while females are 
poised to preserve their function. 
With such strong evolutionarily designed and 
developmentally ensconced mechanisms, sexual 
dimorphism in growth, metabolism and immune function 
are bound to determine cancer risk and therapeutic 
responses. The importance of sex differences as a variable 
in research design should not be ignored. These findings 
should prompt investigators to examine oncogenic 
mechanisms separately in male and female experimental 
systems and to anticipate that therapeutics targeting 
growth regulatory pathways may have differing effects in 
male and female cancer patients. 
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